**第37屆生物夏令營博士生論文競賽申請表**

**37th Biology Summer CAMP Ph.D. Student Award**

**Abstract Application Form**

***Deadline: June 30, 2022***

1. **學生聯絡資訊 (Student Contact Information)**

|  |
| --- |
| **個人資料Personal Information** |
| **中文姓名(Chinese name):** |  |
| **英文姓名(English name):** |  |
| **單位(University/Institute)** | 中文:English: |
| **部門(Department)** | 中文:English: |
| **電話(Phone)** |  |
| **E-mail**  |  |
| **博士班在學證明 (學生證影本)** (**A photocopy of active student ID card)** |

1. **摘要資訊Abstract Information (English)**

|  |  |
| --- | --- |
| **題目(Title):** | Example:The Role of CEACAM6 in Oral Cancer Progression (Title, maximum 15 words,) |
| **作者(authors):** | Example:Ivy Wang1 and Ming-Heng Lin2 (Author names) |
| **Affiliations** | Example:1International Ph.D. Program for Translational Science, Taipei Medical University, Taipei, Taiwan 2Department of Agriculture, Rice University, City, Country |
| **關鍵字(Keywords)****(Up to five keywords )**  |  |
| **Abstract (maximum 300 words)****Font, text size and spacing:** Arial, 12pt and single line spaceExample:Oral squamous cell carcinoma (OSCC) is one of the most common head and neck squamous cell carcinoma (HNSCC) worldwide. Despite the easy access of oral cavity for direct visual examination and advances in treatment for OSCC, the 5-year survival rate remains less than 50%. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol (GPI)-anchored protein, is a heavily-glycosylated tumor antigen and its expression is correlated the poor prognosis of OSCC. CEACAM6 promotes cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn256 (N256) of CEACAM6. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. |
| Corresponding author： |
| \*Signature of corresponding author：\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

\* Signature of corresponding author is required to approve your submission.